Acknowledgement
The authors sincerely thank to Dr. Sung Ho Son at the Vitrosys Inc., Yeongju, Korea for providing ginsenoside Rg3. This study was supported by the grant from the National Research Foundation of Korea (#2014-055-842).
References
- Kim, J. W., S. Y. Jung, Y. H. Kwon, J. H. Lee, Y. M. Lee, B. Y. Lee, and S. M. Kwon. 2012. Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. Cancer Biol. Ther. 13: 504-515. https://doi.org/10.4161/cbt.19599
- Nam, K. Y., J. E. Choi, S. C. Hong, K. M. Pyo, and J. D. Park. 2014. Recent Progress in Research on Anticancer Activities of Ginsenoside-Rg3. Kor. J. Pharm. 45: 1-10.
- Cirone, M., R. L. Di, L. V. Lotti, V. Conte, P. Trivedi, R. Santarelli, R. Gonnella, L. Frati, and A. Faggioni. 2012. Activation of dendritic cells by tumor cell death. Oncoimmunology 1: 1218-1219. https://doi.org/10.4161/onci.20428
- Fucikova, J., P. Kralikova, A. Fialova, T. Brtnicky, L. Rob, J. Bartunkova, and R. Spisek. 2011. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 71: 4821-4833. https://doi.org/10.1158/0008-5472.CAN-11-0950
- Zitvogel, L., O. Kepp, L. Senovilla, L. Menger, N. Chaput, and G. Kroemer. 2010. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res. 16: 3100-3104. https://doi.org/10.1158/1078-0432.CCR-09-2891
- Panaretakis, T., O. Kepp, U. Brockmeier, A. Tesniere, A. C. Bjorklund, D. C. Chapman, M. Durchschlag, N. Joza, G. Pierron, E. P. van, J. Yuan, L. Zitvogel, F. Madeo, D. B. Williams, and G. Kroemer. 2009. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28: 578-590. https://doi.org/10.1038/emboj.2009.1
- Obeid, M., A. Tesniere, F. Ghiringhelli, G. M. Fimia, L. Apetoh, J. L. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, D. Metivier, N. Larochette, E. P. van, F. Ciccosanti, M. Piacentini, L. Zitvogel, and G. Kroemer. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13: 54-61. https://doi.org/10.1038/nm1523
- Cragg, G. M., D. J. Newman, and K. M. Snader. 1997. Natural products in drug discovery and development. J. Nat. Prod. 60: 52-60. https://doi.org/10.1021/np9604893
- Joo, E. J., Y. W. Ha, H. Shin, S. H. Son, and Y. S. Kim. 2009. Generation and characterization of monoclonal antibody to ginsenoside rg3. Biol. Pharm. Bull. 32: 548-552. https://doi.org/10.1248/bpb.32.548
- Gao, J. L., G. Y. Lv, B. C. He, B. Q. Zhang, H. Zhang, N. Wang, C. Z. Wang, W. Du, C. S. Yuan, and T. C. He. 2013. Ginseng saponin metabolite 20(S)-protopanaxadiol inhibits tumor growth by targeting multiple cancer signaling pathways. Oncol. Rep. 30: 292-298. https://doi.org/10.3892/or.2013.2438
- Wang, C. Z., H. H. Aung, M. Ni, J. A. Wu, R. Tong, S. Wicks, T. C. He, and C. S. Yuan. 2007. Red American ginseng: ginsenoside constituents and antiproliferative activities of heat-processed Panax quinquefolius roots. Planta Med. 73: 669-674. https://doi.org/10.1055/s-2007-981524
- Liu, T. G., Y. Huang, D. D. Cui, X. B. Huang, S. H. Mao, L. L. Ji, H. B. Song, and C. Yi. 2009. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 9: 250.
- Zhang, Q., X. Kang, and W. Zhao. 2006. Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem. Biophys. Res. Commun. 342: 824-828. https://doi.org/10.1016/j.bbrc.2006.02.044
- Yi, C., X. B. Huang, and M. Hou. 2005. [Experimental study on effect of chemotherapy combined ginsengnoside Rg3 in treating pulmonary carcinoma]. Zhongguo Zhong. Xi. Yi. Jie. He. Za Zhi. 25: 58-59.
- Hu, S. S., L. K. Zhou, Y. Ba, H. I. Li, and C. H. Zhu. 2011. A meta-analysis of Ginsenoside Rg3 for non- small cell lung cancer. Clin. Oncol. Cancer Res. 8: 175-180. https://doi.org/10.1007/s11805-011-0578-4
- Liu, J. W., J. X. Chen, L. H. Yu, Y. X. Tian, X. Y. Cui, Q. Yan, and L. Fu. 2004. [Inhibitory effect of ginsenoside-Rg3 on lung metastasis of mouse melanoma transfected with ribonuclease inhibitor]. Zhonghua Zhong. Liu Za Zhi. 26: 722-725.
- Xu, T. M., M. H. Cui, Y. Xin, L. P. Gu, X. Jiang, M. M. Su, D. D. Wang, and W. J. Wang. 2008. Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin. Med. J. (Engl.) 121: 1394-1397. https://doi.org/10.1097/00029330-200808010-00012
- Kim, Y. J., W. I. Choi, B. N. Jeon, K. C. Choi, K. Kim, T. J. Kim, J. Ham, H. J. Jang, K. S. Kang, and H. Ko. 2014. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-beta1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance. Toxicology 322: 23-33. https://doi.org/10.1016/j.tox.2014.04.002
- Lee, S. G., B. S. Kim, and J. O. Nam. 2014. Ginsenoside Rg3 induces apoptosis in B16F10 melonoma cells. J. Life Sci. 24: 1001-1005. https://doi.org/10.5352/JLS.2014.24.9.1001
- Oh, S. J., C. K. Ryu, S. Y. Baek, and H. Lee. 2011. Cellular mechanism of newly synthesized indoledione derivative-induced immunological death of tumor cell. Immune Netw. 11: 383-389. https://doi.org/10.4110/in.2011.11.6.383
- Park, D., D. K. Bae, J. H. Jeon, J. Lee, N. Oh, G. Yang, Y. H. Yang, T. K. Kim, J. Song, S. H. Lee, B. S. Song, T. H. Jeon, S. J. Kang, S. S. Joo, S. U. Kim, and Y. B. Kim. 2011. Immuno-potentiation and antitumor effects of a ginsenoside Rg(3)-fortified red ginseng preparation in mice bearing H460 lung cancer cells. Environ. Toxicol. Pharmacol. 31: 397-405. https://doi.org/10.1016/j.etap.2011.01.008